Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Novartis
Medtronic
Queensland Health
McKesson
Accenture
Fish and Richardson
Healthtrust
Citi
Moodys

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,276,250

« Back to Dashboard

Summary for Patent: 7,276,250
Title:Sustained release formulations of oxymorphone
Abstract:Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
Inventor(s): Baichwal; Anand R. (Wappingers Falls, NY), Kao; Huai-Hung (Syosset, NY), McCall; Troy W. (Germantown, TN)
Assignee: Penwest Pharmaceuticals Company (Danbury, CT)
Application Number:10/189,932
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Use; Dosage form;

Drugs Protected by US Patent 7,276,250

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 DISCN No No ➤ Sign Up ➤ Sign Up Y RELIEF OF MODERATE TO SEVERE PAIN ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-005 Feb 29, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y RELIEF OF MODERATE TO SEVERE PAIN ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-002 Jun 22, 2006 DISCN No No ➤ Sign Up ➤ Sign Up Y RELIEF OF MODERATE TO SEVERE PAIN ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-006 Feb 29, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y RELIEF OF MODERATE TO SEVERE PAIN ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-003 Jun 22, 2006 DISCN No No ➤ Sign Up ➤ Sign Up Y RELIEF OF MODERATE TO SEVERE PAIN ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-007 Feb 29, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y RELIEF OF MODERATE TO SEVERE PAIN ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-004 Jun 22, 2006 DISCN No No ➤ Sign Up ➤ Sign Up Y RELIEF OF MODERATE TO SEVERE PAIN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,276,250

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,309,122 Oxymorphone controlled release formulations ➤ Sign Up
8,329,216 Oxymorphone controlled release formulations ➤ Sign Up
9,820,982 Oxymorphone controlled release formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,276,250

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 208484 ➤ Sign Up
Poland 367277 ➤ Sign Up
Poland 207748 ➤ Sign Up
Poland 366430 ➤ Sign Up
Norway 20031018 ➤ Sign Up
Norway 326375 ➤ Sign Up
Norway 20031019 ➤ Sign Up
South Korea 20030048026 ➤ Sign Up
South Korea 20030034171 ➤ Sign Up
Japan 2009114209 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chubb
Cantor Fitzgerald
Healthtrust
Johnson and Johnson
Fish and Richardson
Covington
McKesson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot